GlassScriptPhysician profile
Emma Rogers
NPI 1760239875
$1,443.32
in general payments reported to CMS, 2019-2025
20 companies · $1,106 in 2025
The $1,106 reported for 2025 was more than what 82% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $338 · 2025: $1,106.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,443.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,443.32 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $308.57 | 2024-2025 | Farxiga, Airsupra, Breztri |
| Novo Nordisk INC | $132.39 | 2024-2025 | Rybelsus, Ozempic |
| Otsuka America Pharmaceutical, INC. | $117.09 | 2024-2025 | Rexulti |
| Lundbeck LLC | $106.68 | 2024-2025 | Rexulti |
| Almatica Pharma LLC | $100.75 | 2025 | Teriparatide |
| Aimmune Therapeutics, INC. | $99.42 | 2025 | Zenpep |
| Abbvie INC. | $98.69 | 2024-2025 | |
| Lilly USA, LLC | $92.46 | 2024-2025 | Zepbound, Jardiance, Mounjaro |
| Glaxosmithkline, LLC. | $72.02 | 2024-2025 | Trelegy Ellipta, Arexvy |
| Sumitomo Pharma America, INC. | $56.01 | 2025 | Gemtesa |
| Exact Sciences Corporation | $38.66 | 2024-2025 | Cologuard Collection Kit |
| Boston Scientific Corporation | $35.80 | 2025 | General - Therapies |
| Novartis Pharmaceuticals Corporation | $29.87 | 2024 | |
| Inspire Medical Systems, INC. | $29.63 | 2025 | Inspire |
| Amgen INC. | $28.97 | 2025 | Repatha, Repatha, Otezla |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mylan Specialty L.P. | $28.20 | 2024 | Yupelri |
| Esperion Therapeutics, INC. | $20.74 | 2024 | Nexletol |
| Calliditas Therapeutics US INC. | $19.21 | 2024 | Tarpeyo |
| Neurocrine Biosciences, INC. | $14.54 | 2025 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $13.62 | 2025 | Caplyta |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Emma Rogers listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.